DE602004006388D1 - Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5) - Google Patents
Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5)Info
- Publication number
- DE602004006388D1 DE602004006388D1 DE602004006388T DE602004006388T DE602004006388D1 DE 602004006388 D1 DE602004006388 D1 DE 602004006388D1 DE 602004006388 T DE602004006388 T DE 602004006388T DE 602004006388 T DE602004006388 T DE 602004006388T DE 602004006388 D1 DE602004006388 D1 DE 602004006388D1
- Authority
- DE
- Germany
- Prior art keywords
- trp
- beta
- ltrpc5
- mtr1
- trpm5
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 101000844521 Homo sapiens Transient receptor potential cation channel subfamily M member 5 Proteins 0.000 title 2
- 102100031215 Transient receptor potential cation channel subfamily M member 5 Human genes 0.000 title 2
- 102000003609 TRPM5 Human genes 0.000 title 1
- 101150059135 TRPM5 gene Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/62—Insulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45259603P | 2003-03-05 | 2003-03-05 | |
| US452596P | 2003-03-05 | ||
| PCT/US2004/006697 WO2004079372A1 (en) | 2003-03-05 | 2004-03-04 | Methods and compositions for treating and diagnosing diabetes and related diseases involving beta-trp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004006388D1 true DE602004006388D1 (de) | 2007-06-21 |
| DE602004006388T2 DE602004006388T2 (de) | 2008-01-10 |
Family
ID=32962734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004006388T Expired - Fee Related DE602004006388T2 (de) | 2003-03-05 | 2004-03-04 | Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7087394B2 (de) |
| EP (1) | EP1599732B1 (de) |
| JP (1) | JP2006523104A (de) |
| AT (1) | ATE362108T1 (de) |
| AU (1) | AU2004217441A1 (de) |
| CA (1) | CA2517981A1 (de) |
| DE (1) | DE602004006388T2 (de) |
| DK (1) | DK1599732T3 (de) |
| WO (1) | WO2004079372A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7364867B2 (en) * | 2000-04-17 | 2008-04-29 | The Mount Sinai School Of Medicine | Method of identifying bitter compounds by employing TRP8, a transient receptor potential channel expressed in taste receptor cells |
| EP2332540A1 (de) | 2002-05-21 | 2011-06-15 | Cv Therapeutics, Inc. | Verabreichung von Ranolazine, zur Behandlung von Diabetes |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| GB0217503D0 (en) * | 2002-07-29 | 2002-09-04 | Novartis Ag | Organic compounds |
| WO2006063332A2 (en) * | 2004-12-09 | 2006-06-15 | Perlegen Sciences, Inc. | Markers for metabolic syndrome obesity and insulin resistance |
| US7749730B2 (en) | 2005-11-03 | 2010-07-06 | Redpoint Bio Corporation | High throughput screening assay for the TRPM5 ion channel |
| AU2006311826C1 (en) * | 2005-11-03 | 2011-06-16 | Redpoint Bio Corporation | Hydrazone derivatives and uses thereof |
| WO2007140308A2 (en) * | 2006-05-25 | 2007-12-06 | The Queens Medical Center | Methods of screening for trpm4 modulators of insulin secretion |
| JP2010518008A (ja) * | 2007-02-02 | 2010-05-27 | レッドポイント バイオ コーポレイション | インスリンおよびｇｌｐ−１の放出を調節するｔｒｐｍ５阻害物質 |
| EP2136780A1 (de) * | 2007-02-13 | 2009-12-30 | CV Therapeutics Inc. | Verwendung von ranolazin zur behandlung von herz-kreislauf-erkrankungen |
| WO2008101012A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of non-coronary microvascular diseases |
| WO2008101008A1 (en) * | 2007-02-13 | 2008-08-21 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| US20080233191A1 (en) * | 2007-03-22 | 2008-09-25 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| WO2009036368A2 (en) | 2007-09-14 | 2009-03-19 | Nitto Denko Corporation | Drug carriers |
| KR101035574B1 (ko) | 2009-04-09 | 2011-05-23 | 대한민국 | 제 2형 당뇨병 치료효과를 판정하는 방법 |
| WO2013022948A1 (en) | 2011-08-08 | 2013-02-14 | The Coca-Cola Company | Cell lines comprising endogenous taste receptors and their uses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5932417A (en) * | 1996-10-15 | 1999-08-03 | The Regents Of The University Of California | Method of screening compounds for controlling capacitative calcium ion entry into mammalian cells |
| DE19953167A1 (de) | 1999-11-04 | 2001-07-26 | Univ Mainz Johannes Gutenberg | Mit TRP-Proteinen verwandtes Protein MTR1 und dieses codierende DNA-Sequenz |
| EP1307555A2 (de) * | 2000-07-31 | 2003-05-07 | Millennium Pharmaceuticals, Inc. | 18610, humaner transienter rezeptor und seine verwendungen |
| JP4393065B2 (ja) * | 2000-11-13 | 2010-01-06 | ザ クイーンズ メディカル センター | Ｌｔｒｐｃ７モジュレーターのスクリーニング方法 |
| US20020164645A1 (en) * | 2000-12-29 | 2002-11-07 | The Regents Of The University Of California | Assays for taste receptor cell specific ion channel |
| WO2004076632A2 (en) * | 2003-02-21 | 2004-09-10 | The Queen's Medical Center | Methods of screening for trpm5 modulators |
-
2004
- 2004-03-04 DE DE602004006388T patent/DE602004006388T2/de not_active Expired - Fee Related
- 2004-03-04 EP EP04717456A patent/EP1599732B1/de not_active Expired - Lifetime
- 2004-03-04 JP JP2006509149A patent/JP2006523104A/ja not_active Withdrawn
- 2004-03-04 CA CA002517981A patent/CA2517981A1/en not_active Abandoned
- 2004-03-04 AU AU2004217441A patent/AU2004217441A1/en not_active Abandoned
- 2004-03-04 US US10/794,897 patent/US7087394B2/en not_active Expired - Fee Related
- 2004-03-04 AT AT04717456T patent/ATE362108T1/de not_active IP Right Cessation
- 2004-03-04 DK DK04717456T patent/DK1599732T3/da active
- 2004-03-04 WO PCT/US2004/006697 patent/WO2004079372A1/en active Search and Examination
-
2006
- 2006-06-09 US US11/450,696 patent/US20070031897A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1599732A1 (de) | 2005-11-30 |
| DE602004006388T2 (de) | 2008-01-10 |
| JP2006523104A (ja) | 2006-10-12 |
| EP1599732B1 (de) | 2007-05-09 |
| US20040259160A1 (en) | 2004-12-23 |
| ATE362108T1 (de) | 2007-06-15 |
| CA2517981A1 (en) | 2004-09-16 |
| AU2004217441A1 (en) | 2004-09-16 |
| DK1599732T3 (da) | 2007-07-16 |
| US20070031897A1 (en) | 2007-02-08 |
| US7087394B2 (en) | 2006-08-08 |
| WO2004079372A1 (en) | 2004-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004006388D1 (de) | Verfahren und zusammensetzungen zur diagnose und behandlung von diabetes und assoziierten krankheiten mit beta-trp (mtr1 / ltrpc5 / trpm5) | |
| ATE455463T1 (de) | Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren | |
| Urban | Micro-and nanobiosensors—state of the art and trends | |
| HUP0401590A2 (hu) | Eljárások allogén sziget átültetés védelmére oldható CTLA4 mutáns molekulák alkalmazásával | |
| ATE375999T1 (de) | Zusammensetzungen und verfahren zur behandlung von diabetes | |
| DE60126592D1 (de) | Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs | |
| DE60323340D1 (de) | Verfahren zur herstellung interferierender rna-moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle | |
| DE60233485D1 (de) | Verfahren zur diagnose, behandlung und prävention von knochenverlust | |
| NO20073846L (no) | Ladet termoplastisk resin-basert bitumlinos mastik | |
| DE60223340D1 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
| DE602004031134D1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| DE10337184A1 (de) | Substituierte 3-Pyrrolidin-Indol-Derivate | |
| Cuthbert et al. | Toward precision medicine in psychiatry: The NIMH research domain criteria project. | |
| Klapper et al. | Natural products from reconstructed bacterial genomes of the Middle and Upper Paleolithic | |
| Booth et al. | Observing washing and dressing of stroke patients: nursing intervention compared with occupational therapists. What is the difference? | |
| DE602004021847D1 (de) | Verfahren zur prävention und behandlung von diabetes mit neurturin | |
| Mikolai et al. | Early host–microbe interaction in a peri‐implant oral mucosa‐biofilm model | |
| DE602006009901D1 (de) | Verfahren zur herstellung von 7-ethyl-10-hydroxycamptothecin | |
| DK1504098T3 (da) | Fremgangsmåde til molekyulær udvikling in vitro af proteinfunktion | |
| ATE144326T1 (de) | Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes | |
| Kocsis et al. | Schwann cells and their precursors for repair of central nervous system myelin | |
| Weir | Substance abuse among physicians | |
| Beghini et al. | Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling | |
| SG158739A1 (en) | Aggrecanase molecules | |
| DE69824839D1 (de) | Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |